Retatrutide

Description

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide that activates three receptors: GLP-1, GIP and glucagon. It is one of the first “triple agonists” to reach late-stage clinical trials and one of the most closely followed compounds in metabolic research.

What is Retatrutide?

Retatrutide was developed as a successor to dual GLP-1/GIP agonists such as tirzepatide. Adding glucagon receptor activity is the feature researchers study most, because glucagon signalling is linked to hepatic glucose output and energy expenditure in animal models.

• GLP-1 receptor: glucose-dependent insulin secretion and satiety signalling
• GIP receptor: incretin signalling and adipose tissue metabolism
• Glucagon receptor: hepatic glucose output, lipid metabolism and energy expenditure

Research Applications

• Obesity and energy-balance models
• Insulin resistance and glucose homeostasis
• Hepatic lipid metabolism and fatty-liver models
• Receptor pharmacology comparisons with mono- and dual-agonists

Product Specifications

• Available sizes: 12mg vial, 6mg x 2 vials
• Form: lyophilized powder in a sealed vial
• Purity: ≥99% (HPLC), manufactured in the USA
• Certificate of Analysis available for each batch
• Storage: store lyophilized product at -20°C, protected from light

Further reading: our Retatrutide research guide covers mechanism and published studies in more detail.

For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. Sold to qualified researchers for in-vitro and laboratory research.